A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT #
NCT05519449
Condition(s)
Prostate
Molecular Target(s)
albumin, CD3, PSMA
Drug Classification(s)
Targeted Immunotherapy
Agents(s)
JANX007
Phase(s)
I
Mechanism of Action
JANX007 is a Tumor Activated T Cell Engager therapuetic targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer.
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- How the level of certain molecules (biomarkers) in your blood changes over time while receiving the study agent
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible
- Adequate organ function
- Prior solid organ transplant
- Prior treatment with PSMA-targeted CAR-T cell therapy
- Clinically significant cardiovascular disease
- Active clinically significant infection (bacterial, viral, fungal, mycobacteria or other)
- Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment
- Prior treatment with PSMA-targeted CAR-T cell therapy Prior treatment with PSMA-CD3 engaging bispecific antibodies
- Prior treatment with systemic immunotherapeutic agents, including anti-CTLA4, anti-PD-1, anti-PD-L1, or other checkpoint inhibiting therapeutic antibodies within 28 days prior to the start of study drug
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
UC23-03
N/A
n/a
N/A
Prostate
UCNT
UC23-02
Potent, highly selective, allosteric, orally bioavailable, small molecule inhibitor ofPRC2 via binding the embryonic ectoderm development (EED) subunit
Small Molecule
Not Required
Prostate
UCNT
22-42
ALG.APV-527 binds to both its targets, 4-1BB and 5T4. ALG.APV-527 has the potential to activate T cells and NK cells that are present in the...
Bispecific Antibodies
Not required
Breast, Cervical, Colorectal, Endometrial, Gastric/Gastro-Esophageal, head and neck squamous cell carcinoma, Mesothelioma, Non-Small Cell Lung, Ovarian, Pancreatic, Prostate, Renal cell, urothelial carcinoma
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.